The National Disease Registration Service (NDRS) collects data on all patients diagnosed with cancer in England. Despite much information collected for patients regarding the nature of their disease and how they are treated, analysing outcomes for sarcoma is extremely difficult, due to its complexity involving many types, anatomical locations and affecting all ages.
In 2019 Professor Sandra Strauss was funded by Sarcoma UK to analyse in detail the incidence and survival of sarcoma across types, ages and anatomical locations. In 2022, the Bone Cancer Research Trust joined, and a partnership was formed.
The funding allowed the team to develop the methodology to extract and interpret this complex data from patients across the country. It has already provided a detail understanding of the incidence and survival of soft tissue and bone sarcoma patients and provided insights into the importance of receiving care at sarcoma specialist centres.
There is however much to do, particularly regarding improved diagnosis and equality of care for all sarcoma patients. To continue this work and to ensure key priorities were identified, in July 2024 the Bone Cancer Research Trust and Sarcoma UK organised a Stakeholder meeting attended by healthcare professionals and sarcoma patients.
Based on their input, ASPIRE has been developed to obtain data and provide the evidence needed to reduce inequalities in diagnostic pathways, access to specialist services and treatment, with the aim of improving services and thereby outcomes for sarcoma patients in England.
The 5-year programme is structured around 6 work packages:
Work Package 1 - Earlier and more accurate diagnosis of sarcoma
WP1 will evaluate patient diagnostic pathways for defined groups of patients to better understand those most disadvantaged and improve service provision. The main objective of WP1 is to provide data on which groups of sarcoma patients are being diagnosed too slowly, what their “route to diagnosis” is and where they live.
Impact of WP1: to identify groups at risk, to inform and provide the necessary evidence for the NHS to target improvements for these groups.
Work Package 2 - Access to specialist services for standard of care
Specialist care has been shown to be an important factor in achieving the best outcomes for sarcoma patients.WP2 aims to understand the variation in access to specialist Multidisciplinary Teams (MDTs), surgery in a specialist centre, radiotherapy in a specialist centre and proton beam therapy.
Impact of WP2: to identify groups who are not getting specialist management, so the NHS can implement changes for these groups to improve access.
Work Package 3 - access to novel treatment and innovation
New therapies and innovation in sarcoma treatment can improve outcomes; however, not all patients have equal opportunities to access them. The objective of WP3 is to understand the variation in access to genomic testing which can influence diagnosis and treatment options, clinical trials and new drugs (including compassionate access to chemotherapy drugs) and tumour ablation/ Stereotactic Ablative Body Radiotherapy (SABR).
Impact of WP3: to identify groups who are not accessing new treatments and innovations, so the NHS can implement changes for these groups to improve access.
Work Package 4 - Patient experience
Quality of life for sarcoma patients and access support along the cancer journey has been identified as apriority by the sarcoma community. The objective of WP4 is to evaluate patient experience. Looking at what patient-reported data sources exist and how good they are. As part of WP4, a survey will be sent to sarcoma patients asking what kind of questions they would most like to be answered using patient reported data. A meeting will be organized to discuss these findings and plan a research project using the patient reported data.
Impact of WP4: to better understand patient experience so we can work together to improve it for those most affected.
Work Package 5 - Engagement and dissemination – Data sharing
WP 5 focuses on how the research team will engage with the sarcoma community and share their results. The plan is to build a dashboard where clinicians can see how their local area is performing compared to others. They also aim to create a communication strategy to share their findings with stakeholders, including patients, to disseminate progress and best practice.
Impact of WP5: an effective communication strategy to stakeholders will help to improve and maintain engagement with sarcoma national data projects in the long term, so people can see the positive impact of their data in the real world. Collaboration within NDRS will make sure that sarcomas are always in the discussion and that sarcoma patient data is being used wherever possible, for example in all the regular reporting and outputs that NDRS currently produce on other cancers.
Work Package 6- project management and Governance
WP6 aims to ensure the partnership is running well, progressing and getting regular expert feedback. A steering group made up of experts in different aspects of sarcoma will meet regularly with the project team to discuss new findings and difficulties/barriers.
Impact of WP6: to ensure the multidisciplinary team stays on track, achieves its goals and overcomes unforeseen difficulties with support from experts.
Sponsor Our Research Into Primary Bone Cancer